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Abstract 
Background: Incomplete adherence to antiretroviral therapy (ART) results in virologic failure and resistance. It 
remains unclear which adherence measure best predicts these outcomes. We compared six patient-reported and 
objective adherence measures in one ART-naïve cohort in South Africa.
Methods: We recruited 230 participants from a community ART clinic and prospectively collected demographic 
data, CD4 count and HIV-RNA at weeks 0, 16 and 48. We quantified adherence using 3-day self-report (SR), clinic-
based pill count (CPC), average adherence by pharmacy refill (PR-average), calculation of medication-free days 
(PR-gaps), efavirenz therapeutic drug monitoring (TDM) and an electronic adherence monitoring device (EAMD). 
Associations between adherence measures and virologic and genotypic outcomes were modelled using logistic 
regression, with the area under the curve (AUC) from the receiver operator characteristic (ROC) analyses derived to 
assess performance of adherence measures in predicting outcomes.
Results: At week 48 median (IQR) adherence was: SR 100% (100–100), CPC 100% (95–107), PR-average 103% (95–
105), PR-gaps 100% (95–100) and EAMD 86% (59–94), and efavirenz concentrations were therapeutic (>1 mg/L) in 
92%. EAMD, PR-average, PR-gaps and CPC best predicted virological outcome at week 48 with AUC ROC of 0.73 (95% 
CI 0.61–0.83), 0.73 (95% CI 0.61–0.85), 0.72 (95% CI 0.59–0.84) and 0.64 (95% CI 0.52–0.76) respectively. EAMD, PR-gaps 
and PR-average were highly predictive of detection of resistance mutations at week 48, with AUC ROC of 0.92 (95% CI 
0.87–0.97), 0.86 (0.67–1.0) and 0.83 (95% CI 0.65–1.0) respectively. SR and TDM were poorly predictive of outcomes at 
week 48.
Conclusion: EAMD and both PR measures predicted resistance and virological failure similarly. Pharmacy refill data is 
a pragmatic adherence measure in resource-limited settings where electronic monitoring is unavailable.
Trial registration The trial was retrospectively registered in the Pan African Clinical Trials Registry, number 
PACTR201311000641402, on the 13 Sep 2013 (www.pactr.org). The first participant was enrolled on the 12th July 
2012. The last patient last visit (week 48) was 15 April 2014
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Background
Adherence is critical to realising the clinical and preven-
tion benefits of ART [1–3]. Despite this, there is no gold 
standard identifying adherence levels and patterns that 
place individuals at risk for virologic failure and/or drug 
resistance [4–6].
A variety of ART adherence measures have been used in 
both observational and intervention studies. Self-report 
is the most frequently used method, but is often impre-
cise and overestimates adherence, similar to clinic-based 
pill count [4–7]. Pharmacy refill data also overestimate 
adherence, but have been consistently associated with 
virological failure and mortality [8–10]. Electronic drug 
monitoring methods have been closely associated with 
virologic failure, despite underestimating adherence due 
to storage and ingestion of medications outside of the 
device (pocket-doses) [6, 11, 12]. Therapeutic drug con-
centration monitoring has been associated with virologic 
outcomes, though its precision relative to other adherence 
monitoring approaches is poorly understood [3, 13, 14].
Few studies have directly compared the ability of multi-
ple adherence monitoring methods to predict virological 
failure in one cohort [15–17] or explored their relation-
ship with drug resistance [18].
Our study compared a variety of adherence measures, 
three widely accessible to clinicians in a resource-poor 
setting: self-report (SR), clinic-based pill count (CPC) 
and pharmacy refill data (PR-average); and three requir-
ing additional technology or calculation: therapeutic drug 
monitoring (TDM), calculation of medication free days 
or gaps (PR-gaps) and real-time electronic drug monitor-
ing. All adherence measures were collected in a prospec-
tive ART-naïve cohort starting first-line ART, in order 
to explore which measure best predicted virological or 
resistance outcome at 16 and 48 weeks into treatment.
Methods
Participants and setting
This study is a sub-study of a randomised controlled trial 
recruited at the Hannan Crusaid Treatment Centre, an 
outpatient antiretroviral treatment centre in Cape Town, 
South Africa. This site and the study have been described 
elsewhere [19, 20]. The cohort included ART-naïve adults 
and adolescents (≥12 years) starting first-line ART. Par-
ticipants were eligible for the parent study if they had 
their own mobile phone, signed an informed consent, 
and had either a baseline CD4 count below 350  cells/µl 
or a stage 3 or 4 AIDs-defining illness in keeping with 
the national HIV guidelines for starting ART [20]. All 
patients on the parent study with viral load data available 
at week 16 or week 48 were included in this sub-study.
Standard of care (SoC)
All participants received three group counsellor-
driven treatment preparedness sessions prior to com-
mencing ART [21, 22]. They were visited at home 
by a community care worker to confirm address and 
ascertain home circumstances. All participants com-
menced a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)-based first-line ART regimen. SoC visit 
frequency and procedures are detailed in Additional 
file  1: Table  S1. Counts of pill returns were done at 
each scheduled clinic visit. Those with a raised HIV-
RNA (>1000 copies/ml) or non-optimal clinic-based 
pill count adherence (<90%) received additional adher-
ence support, which included tailored counselling, 
monthly drug dispensing and follow-up home-visits. 
Participants were traced by phone and home visit if 
they were more than 4 weeks late in attending a sched-
uled clinic visit.
Study design and procedures
The parent study was a randomised controlled trial, with 
primary outcome at 48  weeks, investigating the impact 
of mobile phone message reminders when missed doses 
were detected by a real-time electronic adherence moni-
toring device (EAMD) on adherence to ART [20]. This 
device has been used in other resource-limited settings 
[23, 24]. This sub-study includes data from participants 
without reference to study arm.
There were five study visits: screening (week-4), base-
line (week 0), weeks 16, 32 and 48, detailed in Table  1. 
Participants were reimbursed for local travel (~US$2) 
at each visit and for the three on-study visits (weeks 16, 
32 and 48) were given a gift of a T-shirt, bag or mug val-
ued at R80 (~US$8) or less. If participants came to a SoC 
clinic visit but did not attend the corresponding study 
visit, tablet return and virological data were extracted 
from their clinic folder.
Demographic and psychosocial details, including 
age, gender, weight, height as well as assessments for 
depression, anxiety and alcohol use, were collected 
at screening. The 14-question Hospital Anxiety and 
Depression Score (HADS) was used to assess anxi-
ety and depression and the CAGE score used to assess 
alcoholism [25, 26]. Blood was drawn for CD4 cell 
count (FACS Count™, Beckton Dickinson, NJ, USA) 
and HIV-RNA (HIV-1 RNA 3.0 assay®, Bayer Health-
care, Leverkusen, Germany) at baseline, 16  week and 
48 week visits. Mid-dose efavirenz concentrations were 
determined at weeks 16 and 48. The time of blood draw, 
and the self-reported time of most recent ART dosing 
were recorded.
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Adherence data
For pill counts, average pharmacy refill data and self-
recall, the data used was that typically available to clinic 
staff during a consultation with a patient.
Three‑day self‑recall (SR)
At weeks 16 and 48, study staff asked each participant: 
“Did you swallow your pills yesterday/2 days ago/3 days 
ago?” Percent doses taken over 3  days was calculated 
from the participants’ responses. Study staff were not 
part of the clinical team. Data were only available if a par-
ticipant attended the study visit.
Clinic‑based pill count (CPC)
Participants were instructed to bring any remaining tab-
lets to each study visit. CPC adherence was calculated 
using the difference between the number of tablets dis-
pensed and the number returned and dividing by the 
number of days between the date of dispensing and the 
current visit date (adjusted for the number of doses per 
day). At week 16 this would give adherence over the pre-
vious 1 month period (last dispensing visit was the SoC 
visit a week 12) and at week 48 adherence over the pre-
vious 2 month period (last dispensing visit was the SoC 
visit at week 40). For the analyses, only the tablet count 
related to dosing efavirenz, nevirapine or, for those who 
switched to second-line, lopinavir/r dosing was used.
Pharmacy refill: average method (PR‑average)
An electronic dispensing system (iDART) was used at the 
site to record the date of ART dispensed and the quan-
tity given to each participant [27, 28]. Obvious errors, 
such as date and dispensing duplications were removed. 
A cumulative PR-average measure was obtained at week 
16 and week 48 visits by dividing the number of days of 
efavirenz, nevirapine or lopinavir/r tablets each patient 
received between study randomisation date and the visit 
date, by the number of days they were in care over the 
same period. This method averages adherence across the 
whole period in question.
Pharmacy refill: gaps method (PR‑gaps)
This measure used pharmacy dispensing quanti-
ties and refill visit dates to determine the number of 
Table 1 Baseline demographic, clinical treatment and psychosocial characteristics of participants
a All were taking 3TC or FTC as a second NRTI
b 14-question Hospital Anxiety and Depression Score
Variable Full cohort With VL at week 16 With VL at week 48
Number: n 230 160 180
Female sex: n (%) 150 (65.2) 108 (67.5) 121 (67.2)
Age in years: mean (SD) 34.5 (9.1) 34.8 (8.9) 35.0 (9.4)
Height (cm): mean (SD) 164.0 (8.6) 164.1 (8.2) 164.0 (8.1)
Weight (kg): median (IQR) 67.3 (57.8–79.6) 67.2 (58.0–80.0) 68.1 (58.7–80.4)
BMI: median (IQR) 24.3 (21.3–29.8) 24.2 (21.5–29.9) 24.6 (21.5–30.7)
WHO stage: n (%)
 1 84 (36.5) 58 (36.3) 73 (40.6)
 2 47 (20.4) 34 (21.3) 39 (21.7)
 3 75 (32.6) 54 (33.8) 51 (28.3)
 4 24 (10.4) 14 (8.8) 17 (9.4)
CD4 count (cells/mm3): median (IQR) 225 (133–287) 229 (132–288) 233 (144–287)
Log HIV-RNA (copies/ml): median (IQR) 4.9 (4.4–5.4) 4.9 (4.4–5.4) 4.8 (4.4–5.4)
NNRTI at start: n (%)
 Efavirenz 228 (99.1) (98)
 Nevirapine 2 (0.9) 2 (1.2) 2 (1.1)
 NRTI at starta: n (%)
 Tenofovir 225 (97.8) 159 (99.4) 177 (98.3)
 Zidovudine 4 (1.7) 1 (0.6) 3 (1.7)
 Stavudine 1 (0.4) – –
 HADS depression score of 8 or above (borderline or case)b: n (%) 74 (32.1) 55 (34.3) 58 (32.2)
 HADS anxiety score of 8 or above (borderline or case)b: n (%) 89 (38.7) 64 (40.0) 70 (38.9)
 Non-disclosure: n (%) 11 (4.7) 8 (5.0) 7 (3.9)
 CAGE score ≥ 2: n (%) 35 (15.2) 22 (13.8) 25 (13.9)
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medication-free days (days when the participant could 
not have had medication in hand) in each dispensing 
period. The number of medication-free days are sub-
tracted from the number of days in the period, and the 
result divided by the number of days in the period (up to 
week 16 or up to week 48) to give an adherence percent-
age [10]. This method identifies days when it was not pos-
sible for a patient to have taken medication; and might 
be expected to yield lower but potentially more accurate 
median adherence values than the average method.
Therapeutic drug measuring (TDM)
At weeks 16 and 48 visits a sample was taken to quan-
tify mid-dosing interval efavirenz concentrations. Mid-
dosing interval samples were drawn in the morning, 
after dosing the previous evening. Self-reported time of 
the evening dose was recorded. Samples were kept cold 
(4  °C) until transfer to the laboratory within 2–3  h of 
blood draw. Samples were centrifuged at 3500  revolu-
tions/min for 10 min and plasma pipetted into cryovials 
which were labelled and frozen at −80 °C. Efavirenz con-
centrations were analysed using a validated LC–MS/MS 
method. The therapeutic range for mid-dose EFV con-
centrations is 1–4 mg/L.
EAMD data
All participants received the EAMD on study entry to 
record daily ART dosing times. The device (Wisepill®) 
held a week of medication in an internal and removable 
seven compartment pill box container. Participants were 
trained to fill these pill boxes themselves and replace 
them once a week at the same time as they dosed. On 
opening, a signal was sent via the mobile-phone network 
to a secure central computer, thus recording tablet tak-
ing or treatment interruptions in real time. An adherent 
day was defined as any recorded EAMD opening from 
06h00am on that day to 05h59am the following day. Days 
with battery voltage <3660 V or no heartbeat were cen-
sored (dead battery days). The daily EAMD data for each 
participant were downloaded from the Wisepill® server. 
Cumulative adherence data for EAMD was calculated as 
the number of adherent days divided by the number of 




Failure was defined as a single HIV RNA of >400 copies/
ml at week 16 or >40 copies/ml at week 48 [29, 30].
HIV‑1 drug resistance
Genotype resistance tests were done on those with 
HIV RNA  >500 copies/ml (the minimum HIV-RNA 
for amplification) at weeks 16 or 48. Nucleic acid was 
extracted with the NucliSens EasyMag automated 
extraction system (bioMérieux, Boxtel, The Nether-
lands). Genotyping was performed by RT-PCR followed 
by a nested PCR and sequencing of the complete PR 
gene and RT codons 1–262 (HXB2 numbering: HIV-1 
nucleotide positions 2250–4229) and using gene-specific 
sequencing primers [31]. Participants with one or more 
major resistance mutation as defined by the 2014 IAS 
update of drug resistance in HIV-1, causing resistance to 
≥1 of the three drugs in their regimen were classified as 
resistant [32].
Statistical analysis
Data were analysed using Stata 13.0 (Stata Corporation, 
College Station, USA). Descriptive statistics (number, 
percentage, median and interquartile ranges) were used 
to summarise the baseline characteristics of the partici-
pant group and to tabulate the adherence data.
All available adherence data were used from each indi-
vidual who had a HIV-RNA drawn within a 4 week win-
dow around week 16 (weeks 12–20) or a 16 week window 
around week 48 (weeks 32–64) in a per-protocol analy-
sis from the time they entered care until the date of the 
respective viral load.
Univariate and multivariable logistic regression mod-
els were used to explore each adherence measure’s rela-
tionship to virological failure and genotypic resistance 
at weeks 16 and 48. Both outcomes were binary, cat-
egorised as described above. The data for each adher-
ence variable was continuous, although models were 
repeated using categorical variables (binary or quar-
tiles) to assess linearity. For the TDM models, the log10 
values of EFV mid-dose drug concentrations were used, 
as log10 values shift the distribution curve of the EFV 
concentration values toward normal for regression 
modelling.
Other variables included in the models (age, baseline 
CD4 cell count and baseline HIV-RNA) were specified 
prior to the analysis. Receiver Operator Characteris-
tics (ROC) were generated to view the overall predictive 
power of the univariate and multivariable models. The 
area under the curve derived from the ROC (AUC ROC), 
with 95% confidence intervals, was used to compare the 
prediction of virological failure or resistance by each 
adherence measure. AUC ROCs were compared using 
non-parametric methods.
Results
Two-hundred-thirty antiretroviral naïve HIV-positive 
participants were recruited onto the study between 09 
July 2012 and 09 April 2013. Figure 1 is a flow diagram of 
study participants. Baseline characteristics are described 
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in Table  1. The cohort is typical of other African ART 
cohorts, with a predominance of women. The majority 
were clinically well. More than a third of the cohort had 
anxiety or depression scores (>8) that required further 
assessment and 15% were alcoholic on CAGE (score of 
≥2). These data did not significantly impact on adherence 
in the parent study [20]. A minority had not disclosed 
their HIV-status to any other person.
Antiretroviral therapy
Efavirenz-based ART was initiated in 228 participants 
and the remaining two started twice-daily nevirapine-
based ART. Both regimens were given with two back-
ground nucleoside reverse transcriptase inhibitors. 
Tenofovir/3TC were used in 97.8% (Table 1). The major-
ity of participants were taking three tablets once a day 




• 29 did not return for ART
• 25 missed by study staff
• 18 missed randomisaon
• 12 accessed treatment 
elsewhere
• 3 not eligible 
• 2 too early to treat (CD4>350)
Week 48:
Aended week 48 study visit: 186 (80,8%)
- of whom 180 had viral load data
Transferred to other clinics: 16 (7.0%) 
Lost to follow up: 19 (8.3%)
Died: 8 (3.5%)
Withdrew consent: 1 (0.4%)
Week 16:
Aended week 16 study visit: 174 (75.7%)
- of whom 160 had viral load data
In care but missed study visit: 34 (14.8%)
Transferred to other clinics: 9 (3.9%)
Lost to follow up: 8 (3.5%)
Died: 4 (1.7%)
Withdrew consent: 1 (0.4%)
Fig. 1 Flow diagram describing the outcome of the 319 individuals screened and the 230 individuals randomised to the study
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Retention in care (Fig. 1)
At the end of the study 186 participants remained in 
care (80.8%) at the study site and a further 16 (7.0%) had 
transferred to care elsewhere. Eight participants (3.5%) 
had died and 19 (8.3%) were lost to follow up i.e. had not 
attended the clinic for more than 12 weeks and were not 
known to have transferred out or to have died. One par-
ticipant withdrew consent.
Adherence measures
Table  2 describes the median adherence by each meas-
ure at weeks 16 and 48, for all participants with a HIV-
RNA drawn at that visit. Three-day self-recall (SR) and 
efavirenz therapeutic drug monitoring (TDM) data were 
only available if study visits were completed. Clinic-based 
pill count (CPC) and pharmacy refill data (PR-gaps and 
PR-average) were available for all those who attended 
the clinic. EAMD data were available for all study par-
ticipants. There were 82,311 participant dosing days 
recorded, and of these, 8362 (10.1%) were dead battery 
days.
The subjective measure, SR, gave the highest adher-
ence with the most individuals reporting 100% adherence 
(median 100%, IQR 100–100%). CPC, PR-gaps and PR-
average also gave perfect or close to perfect adherence at 
week 16 and 48, but widened inter-quartile ranges high-
lighted some variations within the participants. Cumu-
lative adherence by EAMD showed the lowest median 
adherence at both visits: 93% (IQR 74–98%) at week 16 
and 86% (IQR 59–94%) at week 48. Median efavirenz 
concentrations were 2.3 (IQR 1.6–4.4) mg/L at week 16, 
and 2.1 (IQR 1.5–3.4) mg/L at week 48, within the cur-
rently recognised therapeutic range of 1.0–4.0  mg/L at 
both time points.
Virological outcome
At week 16, 160 participants had HIV-RNA available 
within the 12–20  week window and 146 (91.2%) were 
suppressed to ≤400 copies/ml (Table 1). At week 48, 180 
had a HIV-RNA available, of whom 153 (85.0%) were 
suppressed to ≤40 copies/ml (Table  1). Three partici-
pants switched to second-line therapy between weeks 32 
and 48 of the study.
Virological failure prediction models
At week 48, adherence measured by EAMD, PR-aver-
age, PR-gaps and CPC significantly predicted virologi-
cal failure both in univariate and multivariable analyses. 
The odds ratio for these models gives the reduction in 
the risk of failure for each 10% increase in adherence as 
quantified by the specified method (Table  3). Neither 
TDM nor SR adherence predicted failure. For all multi-
variable models, an increased CD4 cell count at baseline 
was associated with reduced odds of failure (continuous 
model examples are presented in Additional file 1: Table 
S2; and categorical model examples in Additional file 1: 
Table S3).
ROC curves were generated from the univariate mod-
els at 48 weeks, and AUC ROCs were derived to allow for 
comparison of predictive value across adherence meth-
ods (Fig.  2a). Cumulative measures EAMD (ROC AUC 
0.73, 95% CI 0.61–0.83), PR-average (ROC AUC 0.73, 
95% CI 0.61–0.85), PR-gaps (ROC AUC 0.72, 95% CI 
0.59–0.84) and CPC (ROC AUC 0.64, 95% CI 0.52–0.76) 
best predicted failure at week 48.
At week 16, analyses showed that both PR-average and 
PR-gaps were predictive of failure, in both univariate 
and multivariable models. Log10 EFV concentration also 
reached significance in the univariate model (for every 10 
times or 1 log increase in EFV concentration, the odds of 
failure reduced by 83%), but the other adherence meas-
ures, including EAMD, did not significantly predict fail-
ure at week 16 (Table 3).
Resistance outcome
Twelve of the fourteen participants whose HIV-RNA was 
>400 copies/ml at week 16 were successfully amplified 
when sent for HIV-1 resistance genotyping. Two partici-
pants had no major resistance mutations. Eight (66.7%) 
participants expressed the K65R mutation-conferring 
resistance to tenofovir, and three the M184 V mutation- 
conferring resistance to lamivudine/emtricitabine. All 10 
who expressed resistance had NNRTI mutations, includ-
ing L100I, K101E, K103N, V106M, Y181C, Y188C/Y/L, 
G190A/G/S and H221HY. Despite only efavirenz and 
nevirapine being used, mutations conferring resistance 
to etravirine and rilpivirine were noted in three partici-
pants: one each of V90I, E138A and V179D.
Table 2 Median adherence percentage with  inter-quartile 
range at each study visit, by adherence measure
Self-report and EFV concentrations are measured on the date of the visit. 
Tablet counts cover the 30 days (week 16) or 60 days (week 48) before the visit. 
Pharmacy refill and EAMD adherence are cumulative data from baseline to latest 
time in care
a Cumulative per protocol measures
n Week 16 n Week 48
Self-report (%): median (IQR) 140 100 (100–100) 169 100 (100–100)
Pill count (%): median (IQR) 160 100 (92–100) 178 100 (95–107)
Average pharmacy refill (%): 
median (IQR)a
158 104 (101–105) 178 103 (95–105)
Gaps pharmacy refill (%): 
median(IQR)a
158 100 (100–100) 178 100 (95–100)
EAMD adherence (%): 
median (IQR)a
160 93 (74–98) 180 86 (59–94)
EFV concentration (mg/L): 
median(IQR)
136 2.3 (1.6–4.4) 156 2.1 (1.5–3.4)
Viral suppression: n (%) 160 146 (91.2) 180 153 (85.0)
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Twenty-seven participants had a HIV RNA of >40 cop-
ies/ml at week 48. Eleven of the fourteen (51.9%) who 
had HIV RNA  >500  copies/ml had resistance genotyp-
ing successfully completed. One had no major resist-
ance mutations. Two (18%) participants expressed the 
K65R mutation and four (36%) the M184 V mutation. As 
at week 16, the majority of the remaining mutations, in 
all 11 who expressed resistance, were NNRTI mutations, 
including L100I, K101E, K103N, V106M, Y181C, G190A, 
H221HY and F227L. Again, mutations to etravirine and 
rilpivirine were noted in 3 participants: one with E138A 
and two with V179D.
Resistance prediction models
As for virological failure, each adherence variable was mod-
elled against the risk of resistance using both univariate 
and multivariate logistic regression models for prediction. 
Adherence as quantified by EAMD, PR-average, PR-gaps, 
TR and log10 EFV concentration were all significantly pre-
dictive of resistance in both univariate and multivariable 
analyses at week 48 (Table  3). SR was non-significant in 
either model. Reduced age and decreased CD4 cell count at 
baseline significantly increased the odds of resistance in all 
multivariable models (data not shown). AUC ROC values 
were obtained to allow for inter-measure comparison of 
resistance prediction at weeks 48 and 16. While cumulative 
EAMD best predicted resistance with the narrowest confi-
dence intervals (AUC ROC 0.92, 95% CI 0.87–0.97), it was 
not significantly better than either PR measure (PR-average 
AUC ROC 0.86, 95% CI 0.67–1.0; PR-gaps AUC ROC 0.83, 
95% CI 0.65–1.00) at week 48.
In contrast, only PR-average predicted resistance at 
week 16 (AUC ROC 0.72, 95% CI 0.57–0.90) (Table  3). 
Reduced age and decreased CD4 cell count at baseline 
significantly increased the odds of resistance in all mul-
tivariable models at week 16. All data on which theses 
analyses are based are available in Additional file 2.
Discussion
We found high levels of adherence using both short-
term and cumulative measures. Three-day SR yielded 
the highest adherence estimate, but was not a significant 
predictor of either viral suppression or resistance. This 
is consistent with findings which show that while short-
term SR measures are widely utilised and useful for clini-
cal intervention [33], they overestimate adherence, likely 
due to recall and social desirability bias [34–37], and are 
unreliable measures for research purposes.
In contrast, four of the five objective adherence meas-
ures effectively predicted virological failure: CPC, PR-
average, PR-gaps and EAMD data. Cumulative PR 
measures (PR-average and PR-gap) were among the best 
predictors of virological failure and resistance at 48 and, 
of note, PR-average was the only predictor of resistance 
at week 16. PR-average has previously been reported to 
be a reliable predictor of virological outcomes and mor-
tality [3, 8, 9], while our group demonstrated that short 
term PR-gap can predict failure on second-line ART 
[10]. Software to calculate PR-average or PR-gaps could 
Table 3 The table below  presents odds ratios (OR) or 
adjusted odds ratios (aOR) with 95% confidence intervals 
(CI) for  failure or resistance given  a 10% increase in  the 
adherence variable (or a 1 log increase in  EFV concentra-
tion) in each logistic regression model
Univariate models use only the adherence variable in the model with the 
outcome variable, multivariable models include the adherence variable 
and three baseline variables (CD4 cell count, log HIV-RNA and age) with the 
outcome variable. There are four outcome variables: the risk of virological 
failure to >40 copies/ml at week 48, the risk of virological failure to >400 copies/
ml at week 16, the risk of resistance (presence of ≥1 IAS major mutation at 
genotyping) at weeks 16 and 48
a EAMD = electronic adherence monitoring device data; PR-average = average 
pharmacy refill data; PR-gaps = pharmacy refill gaps data; CPC = clinic-based 
pill count data; EFV = efavirenz mid-dosing interval data; SR = 3-day self-recall 
data
Those results that are significant (p < 0.05) are in italics
Adherence 
measure
Univariate model Multivariable model
OR (95% CI) p value aOR (95% CI) p value
Virological failure (>40 copies/ml) at week 48
 EAMDa 0.87 (0.82–0.94) <0.001 0.89 (0.82–0.95) 0.001
 PR-average 0.78 (0.70–0.88) <0.001 0.78 (0.69–0.87) <0.001
 PR-gaps 0.69 (0.56–0.82) <0.001 0.68 (0.56–0.82) <0.001
 CPC 0.89 (0.82–0.96) 0.004 0.88 (0.80–0.96) 0.004
 Log10EFV 0.40 (0.16–1.03) 0.059 0.52 (0.19–1.37) 0.184
 SR 0.98 (0.89–1.08) 0.698 0.98 (0.88–1.09) 0.720
Resistance (presence of ≥1 major mutation) at week 48
 EAMD 0.74 (0.64–0.87) <0.001 0.68 (0.53–0.88) 0.003
 PR-average 0.77 (0.69–0.87) <0.001 0.77 (0.66–0.89) <0.001
 PR-gaps 0.74 (0.65–0.85) <0.001 0.77 (0.66–0.89) 0.001
 CPC 0.85 (0.77–0.94) 0.002 0.82 (0.69–0.98) 0.031
 Log10EFV 0.14 (0.04–0.45) 0.001 0.14 (0.02–0.78) 0.025
 SR 0.92 (0.83–1.02) 0.102 0.92 (0.78–1.08) 0.316
Virological failure (>400 copies/ml) at week 16
 EAMD 0.93 (0.86–1.01) 0.085 0.96 (0.87–1.06) 0.459
 PR-average 0.68 (0.55–0.83) <0.001 0.66 (0.50–0.73) 0.004
 PR-gaps 0.64 (0.51–0.82) <0.001 0.64 (0.47–0.88) 0.006
 CPC 0.89 (0.78–1.03) 0.133 0.94 (0.78–1.13) 0.491
 Log10EFV 0.17 (0.04–0.75) 0.020 0.20 (0.03–1.47) 0.115
 SR 0.92 (0.83–1.03) 0.163 0.98 (0.83–1.01) 0.765
Resistance (presence of ≥1 major mutation) at week 16
 EAMD 0.93 (0.85–1.01) 0.085 0.96 (0.86–1.07) 0.435
 PR-average 0.85 (0.72–0.99) 0.036 0.87 (0.72–1.06) 0.171
 PR-gaps 0.85 (0.71–1.01) 0.066 0.88 (0.69–1.11) 0.287
 CPC 0.90 (0.80–1.01) 0.069 0.93 (0.82–1.06) 0.316
 Log10EFV 0.34 (0.08–1.81) 0.228 0.43 (0.07–2.66) 0.362
 SR 0.93 (0.83–1.03) 0.147 0.97 (0.85–1.11) 0.647
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Fig. 2 Prediction of virological failure or resistance by each adherence measure at week 48. Receiver operating characteristic (ROC) curves showing 
prediction of virological failure (>40 copies/ml) and resistance at week 48 by six adherence measures. Univariate model data are shown. a Prediction 
of virological failure to <40 copies/ml at week 48 using adherence measures at week 48. b Prediction of resistance at week 48 using adherence 
measures at week 48. *Compared to week 48 cumulative EAMD data
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easily be added to electronic dispensing systems, which 
are widely used in resource-limited settings. Program-
matic review of adherence using PR methods could be 
implemented immediately.
CPC is not widely recommended as it is subject to “pill 
dumping” and can be complex to perform in a large clinic 
[3]. Nonetheless, CPC, which is a standard of care proce-
dure in our clinic, performed well in this study and was 
predictive of virological failure and resistance at week 48.
While EAMD data were among the best at predicting 
outcome in this study at week 48, EAMDs are not rou-
tinely used in clinical care. However, recent data shows 
EAMD can reduce costs associated with HIV-RNA mon-
itoring and real-time devices can detect early virologic 
rebound before established failure [3, 38, 39]. With the 
availability of newer, more affordable real-time technolo-
gies, electronic strategies should be reconsidered [40].
By altering the distribution of efavirenz concentrations 
through the use of log values in the regression model, we 
found that the log values of mid-dose EFV concentration 
were predictive of resistance at week 48, with wide con-
fidence intervals, but not of failure. Most drug concen-
trations were therapeutic, possibly reflecting white coat 
pre-visit dosing, leaving few with concentrations below 
therapeutic where virological failure would be more 
likely. The few participants with sub-therapeutic concen-
trations limit the interpretation of this data. Larger stud-
ies including more participants with sub-therapeutic EFV 
concentrations are needed to adequately explore the abil-
ity of TDM to predict virological failure and resistance.
Most participants remaining in care at weeks 16 and 48 
had virological suppression. The majority of those who 
had detectable HIV RNA also had resistance that would 
compromise at least one drug in their antiretroviral regi-
men, even at 16 weeks. Only the PR-average method pre-
dicted this early resistance. Using early pharmacy refill 
data to predict failure is practical and easy to achieve 
both for an individual and on a programmatic level. 
EAMD data was highly predictive of resistance at week 
48, as were both PR measures and, to a lesser extent CPC.
It is interesting that while many of the adherence meas-
ures are predictive of viral or resistance outcomes at week 
48, far fewer are predictive at week 16. This might suggest 
that measures of adherence which cover a longer period 
of dosing are more accurate e.g. cumulative EAMD, PR 
methods and CPC over 2-months. Conversely, adherence 
data collected over a shorter window were not predictive 
e.g. 3-day self-report, spot EFV concentrations and CPC 
over 1 month.
The prospective collection of multiple adherence meas-
ures in a single cohort is the strength of our study as it 
has allowed direct comparison of these measures—a 
comparison rarely achieved [13, 16]. Our study was based 
on maximum use of existing adherence data and used a 
per protocol approach to analysis, with those who did not 
have virological data at weeks 16 or 48 treated as missing 
for the predictive models. Losses to care in this cohort 
were similar to those previously reported at this site. All 
participants had data included in the cumulative adher-
ence measures [41, 42].
Both genotyping and viral load testing are costly and 
funding to conduct baseline resistance testing and con-
firmatory viral loads at week 48 was not available. This is 
a study limitation. In addition, SR data was only collected 
as a 3-day recall at each visit and CPC data were only 
available for the 1 or 2 months preceding the week 16 or 
48 visit and not over the complete study period. These 
measures may have performed better being collected 
over a longer or cumulative period of time.
Conclusion
Adherence as measured by CPC, PR measures and 
EAMD were the best predictors of resistance and viro-
logical failure in this prospective study. Pill counting can 
be implemented at any clinic, and pharmacy refill data is 
already widely available and an immediately implementa-
ble option, particularly in resource-poor settings. Con-
sideration should also be given to the use of electronic 
measures as adherence monitoring strategies as costs 
reduce [40].
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